Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 5/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6107053 | 0.86 | ADORA1 (0.41) | ADORA1KMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL14667356 | 0.83 | ADORA1 (0.46) | ADORA1KMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL9948446 | 0.83 | KMT2A (0.52) | ADORA1KMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL2033687 | 0.80 | HTT (0.51) | ADORA1KMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL10851267 | 0.77 | S1PR2 (0.41) | KMT2AMEN1HTTCYP1A2HSD17B10 | |
| SCHEMBL16316421 | 0.75 | ADORA1 (0.56) | ADORA1KMT2AMEN1L3MBTL1POLB | |
| SCHEMBL2587336 | 0.75 | S1PR2 (0.62) | ADORA1KMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL10847312 | 0.75 | S1PR2 (0.42) | KMT2AMEN1HTTCYP1A2CYP3A4 | |
| SCHEMBL25707106 | 0.75 | L3MBTL1 (0.47) | ADORA1KMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL10857111 | 0.72 | KMT2A (0.49) | KMT2AMEN1HTTPOLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7153862-B2 | αv integrin receptor antagonists | MERCK & CO., INC. (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2006-11-09 | — | — | US | disclosed |
| EP-1656387-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005012324-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-6693101-B2 | ALKANOIC ACID DERIVATIVE; INTEGRIN RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2004-02-17 | — | — | US | disclosed |
| US-20040019037-A1 | Alpha V integrin receptor antagonists | ASKEW BEN C (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1254116-A4 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-1254116-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2002-11-06 | — | — | EP | disclosed |
| US-20010053853-A1 | Alpha V integrin receptor antagonists | MERCK & CO., INC. | 2001-12-20 | — | — | US | disclosed |
| WO-2001053262-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | ADORA1 280/4885KMT2A 1246/4885MEN1 3605/4885 |
| US-20040019037-A1 | Alpha V integrin receptor antagonists | ITGAV, ADGRE5, ITGA5 | ADORA1 170/4885KMT2A 3784/4885MEN1 2715/4885 |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | ADORA1 280/4885KMT2A 1246/4885MEN1 3605/4885 |
| US-20010053853-A1 | Alpha V integrin receptor antagonists | ITGAV, ADGRE5, ITGA5 | ADORA1 170/4885KMT2A 3784/4885MEN1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.